Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
N0159093858
Study information
Scientific title
Peak flow in heart failure
Acronym
Study hypothesis
Does treatment with ipratropium bromide (Atrovent) improve peak flow and associated symptoms?
Ethics approval
Not provided at time of registration
Study design
Randomised double blind trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Condition
Cardiovascular: Heart failure
Intervention
Ipratropium bromide vs standard practice
Intervention type
Drug
Phase
Not Applicable
Drug names
Ipratropium bromide
Primary outcome measures
Improvement in peak flow rates and other symptoms.
Secondary outcome measures
Not provided at time of registration
Overall trial start date
01/02/2001
Overall trial end date
01/04/2004
Reason abandoned
Eligibility
Participant inclusion criteria
Patients with heart failure
Participant type
Patient
Age group
Not Specified
Gender
Not Specified
Target number of participants
Not provided at time of registration
Participant exclusion criteria
Not provided at time of registration
Recruitment start date
01/02/2001
Recruitment end date
01/04/2004
Locations
Countries of recruitment
United Kingdom
Trial participating centre
North Tees & Hartlepool NHS Trust
Stockton-on-Tees
TS19 8PE
United Kingdom
Sponsor information
Organisation
Department of Health (UK)
Sponsor details
Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom
Sponsor type
Government
Website
Funders
Funder type
Hospital/treatment centre
Funder name
North Tees and Hartlepool NHS Trust (UK)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary